Articles On Prescient Therapeutics (ASX:PTX)

 Percheron’s Duchenne muscular dystrophy trial has been a compete flop Canaccord Genuity says Opthea shares are worth at least double their current price Neurizon asks US regulator for motor neurone disease trial go-ahead   Firstly, full...

Highlights    Enhanced understanding of SCLC subtypes drives tailored treatment approaches.   Immunotherapy and antibody-drug conjugates emerge as key strategies.   Asia-Pacific region identified as a critical area for further clinica...

Alive and Kicking is renowned biotech journo Tim Boreham’s new daily wrap covering morning movers and shakers of note in the ASX Healthcare sector, Monday through Thursday.   Prescient Therapeutics chief Steve Yatomi-Clarke resigns to hea...

Cynata Therapeutics flags three trial results in the short term for three different conditions, including diabetic leg ulcers Prescient Therapeutics prepares for a blood cancer trial and potential fast-track approval Pacific Edge chairman...

Highlights PTX-100 Phase 1b trial in r/r TCL has been completed with encouraging results. Phase 2 registration trial is under planning phase. PTX-100 has been granted US Orphan Drug designation by US FDA in all TCLs. PTX-100 of Pr...

Highlights Prescient Therapeutics has received AU$2.4 million as R&D Tax Incentive rebate for FY23. R&D Tax Incentive is given under a government program providing firms cash refunds of up to 43.5% of eligible R&D expenses....

Highlights PTX is advancing its diversified pipeline of cancer therapies, backed by a world-class research, clinical and commercial team. PTX-100 Phase 1b trial data is expected in December 2023. Pre-clinical data of CellPryme surpass...

‘Big pay day’ for Prescient Therapeutics, says Pitt Street Aerometrex to benefit from the seismic shifts of Artificial Intelligence   Pitt Street Research has sent us its thesis on biotech stock, Prescient Therapeutics (ASX:PTX), with a v...

Highlights Prescient Therapeutics’ abstract for PTX-100 has been published on the American Society of Hematology (ASH) website PTX-100 Phase 1b study is ongoing with patients with refractory and relapsed TCL The trial results are anti...

  PTX-100 Phase 1b study nearing completion; data to be reported at major haematology conference in December CellPryme pre-clinical data continues to surpass current cell therapy approaches Business development meetings with international...

Australian clinical stage oncology company Prescient Therapeutics (ASX: PTX) is set to present the exciting results from its latest cancer treatment study at the world’s largest hematology event. Prescient’s abstract for results of its phas...

Highlights Abstract for the Phase 1b cancer trial results will be presented at the world’s largest haematology conference. The latest development is a validation to PTX work in T cell lymphomas, an area of unmet clinical need. The ASH...

Prescient Therapeutics (ASX:PTX) has announced that its abstract for the results of a Phase 1b study in T-cell lymphomas has been accepted for poster presentation at the American Society of Hematology annual meeting in December....

According to the World Health Organisation (WHO), cancer is the leading cause of death globally. WHO defines cancer as a generic term for a large group of diseases that can affect any part of the body with malignant tumours and neoplasms. W...

Clinical stage oncology company Prescient Therapeutics (ASX: PTX) has reported a solid end to financial year 2023 which it says has set the stage for a pivotal 12 months to come and beyond. Front and centre of the company’s strategy is comm...

  Steven Yatomi Clarke – CEO and Managing Director – Prescient Therapeutics (ASX:PTX) is a clinical-stage biotech company developing personalised medicine approaches to cancer, including targeted and cellular therapies.

Tim Boreham highlights the potential for cancer treatment biotech Arovella Therapeutics. By Tim Boreham ASX code: ((ALA)) Share price: 4.8 cents Shares on issue: 899,149,698 Market cap: $44 million Chief executive officer: Dr Michael Baker...

Orphan diseases are those impacting less than 200,000 patients Orphan drug designation ensures an exclusivity period for pharma companies The average orphan drug in the US retails for US$7,000 per month   Rare or ‘Orphan’ diseases affect...

This content is created by Smallcaps Authors. [Author : Imelda Cotton] Clinical stage oncology company Prescient Therapeutics (ASX: PTX) will present two of its abstracts at an annual conference of the International Society of Cell &...

Highlights OmniCAR and CellPryme abstracts of Prescient have been accepted for showcasing at the annual meeting of the prestigious International Society of Cell & Gene Therapy (ISCT) The two abstracts would also be published in the...

Highlights Dr Ellen Feigal is serving on the Boards of NASDAQ-listed biotechnology companies Xencor Inc, and NextCure She has been included in Prescient Therapeutics' Board as a US-based independent, Non-Executive Director Dr Feigal h...

Highlights Prescient has informed about progress with regard to its PTX-100 therapy and cell therapu OmniCAR The Company has received "excellent" results from the clinical trial of PTX-100 therapy (T Cell Lymphoma) CellPryme being eva...

Amid the bombed-out biotech sector, early-stage developers of a new cancer immunotherapy have caught the eye of investors after some promising clinical news. These companies are working on so-called CAR-T therapies, which work by ‘superchar...

Stockhead’s resident health and biotech expert Tim Boreham is putting down the microscope and picking up the microphone for another instalment of The Health Kick Podcast.  In this episode Tim chats to Steven Yatomi-Clarke, CEO of Prescient...

Prescient Therapeutics is hoping to follow in the footsteps of Neuren Pharmaceuticals after positive results from its latest Phase 1b clinical trial. Prescient Therapeutics (ASX:PTX) will seek approval from the US Food and Drug Administrat...

This content is created by Smallcaps Authors. [Author : Filip Karinja] Clinical-stage oncology company Prescient Therapeutics (ASX: PTX) has announced continuing positive results in the PTX-100 phase 1b expansion cohort for relapsed and r...

Telix Pharma gets FDA approval Prescient shows good data from Phase 1b clinical trial Incannex plans to open multiple psychedelic-assisted psychotherapy clinics in Australia and overseas   Telix Pharma (ASX:TLX) announced the US FDA has a...

Highlights Prescient Therapeutics (ASX:PTX) has updated on continued promising results in PTX-100 T Cell Lymphoma Phase 1b Cohort. The compound continues to exhibit an excellent safety profile, the company says. The latest data has ex...

ShareCafeBig gains from tech and consumer discretionary boost ASX 0.05% by Peter Milios   Australian shares remained resilient to ex-dividend falls in major companies, including BHP (ASX:BHP), Rio Tinto (ASX:RIO), and CSL (ASX:CSL), as most...

ASX 200 adds just 0.1% because it was literally the least it could do. Aussie tech stock surge negated by Doctors and Miners having a bad hair day. Two ASX-listed lithium players are under attack over alleged corruption in Africa, of all p...

The granting of an Orphan Drug Designation for PTX-100 gives Prescient guaranteed market exclusivity of 7 years. The US FDA has just granted Prescient Therapeutics (ASX:PTX)’s PTX-100 additional Orphan Drug Designation (ODD) for the treatme...

ShareCafeInformation Technology lifts ASX 0.1% at noon by Peter Milios   Information Technology has boosted the S&P/ASX 200 0.1 per cent higher at 7311.3 at noon. The reason for this was the announcement from Xero (ASX:XRO), outlining t...

This content is created by Smallcaps Authors. [Author : Imelda Cotton] Clinical stage oncology company Prescient Therapeutics (ASX: PTX) has secured an orphan drug designation from the US Food and Drug Administration (FDA) for its lead ca...

ShareCafeStocks of the Hour: PTX, LIN, SLS                    Prescient Therapeutics (ASX:PTX) has announced that the US FDA Grants Orphan Drug Designation to PTX-100 for broader TCL indications. Prescient Managing Director and CEO St...

US Food and Drug Administration (FDA) grants Prescient Therapeutics (PTX) broad orphan drug designation (ODD) for its PTX-100 drug The company had applied for ODD for the treatment of cutaneous T-cell lymphomas (CTCL), but the FDA grante...

09 Mar 2023 - A snapshot of the stocks on the move featuring Prescient Therapeutics (ASX:PTX), Lindian Resources (ASX:LIN) and Solstice Minerals (ASX:SLS).

Highlights Prescient Therapeutics’ PTX-100 therapy previously held Orphan Drug Designation (ODD) for peripheral TCL The US Food and Drug Administration has now granted PTX-100 ODD for all T-cell lymphomas including cutaneous TCL This...

A little-known ASX biotech stock is setting the bar high today. In morning trade on Thursday, the All Ordinaries Index (ASX: XAO) is up a slender 0.1%. But shares in this biotechnology company rocketed 29% in earlier trade. At the time of...

Clinical-stage oncology company Prescient Therapeutics (ASX:PTX) has announced that the US FDA has granted Orphan Drug Designation for PTX-100 for the treatment of T-cell lymphomas, including cutaneous TCL.

Stockhead’s Top 10 at 10, published at 10.30am each trading day, highlights the best (and worst) performing ASX stocks in morning trade using live data. It’s a short, sharp update to help frame the trading day by showing the biggest movers...

Highlights Prescient Therapeutics’ latest half-year report focuses on progress made on its targeted and cell therapies. The ASX-listed company, which is committed to developing novel cancer therapies, has also reported about new collabo...

Highlights Prescient (ASX:PTX) highlights that its latest quarter achievements have strengthened its mark as an evolving player for the next generation of personalised therapies for cancer. During the quarter, PTX-100 showed promising...

Highlights Prescient intends to modify the study protocol for enrolling additional CTCL patients for the clinical trial of PTX-100 Ongoing development of OmniCAR platform, towards clinical trials CellPryme-M can seamlessly integrate i...

Highlights Prescient marked a number of developments in 2022, cementing its lead in cancer therapy innovation. PTX-100, being studied in a type of rare blood cancer, continued to demonstrate encouraging clinical activity with a very fa...

Highlights: Prescient is developing a portfolio of targeted therapies and cell therapies for cancer treatment. In September, the company joined hands with MD Anderson Cancer Center. The company believes CellPryme is now ready for clin...

Stockhead’s Year in Review video series is a yearly wrap up address from company leaders showcasing latest achievements, discoveries and developments of emerging ASX companies.  In this instalment Steven Yatomi-Clarke, CEO and managing dire...

Prescient’s PTX-100 Phase 1b study shows encouraging responses on a patient population that is notoriously difficult to treat. Clinical stage oncology company Prescient Therapeutics (ASX:PTX) has revealed that its PTX-100 Phase 1b clinical...

A study by Prescient Therapeutics (ASX: PTX) into the effects of lead drug PTX-100 on relapsed and refractory T-cell lymphomas (TCL) continues to show encouraging clinical activity in a difficult-to-treat patient population. The study compr...

27 new biotech companies listed on the ASX the last two years Australian companies need access to US capital to grow The AusBiotech investment conference kicks off next week in WA   The Covid-19 pandemic put Australia’s biotechnology sect...